Vaxart has reported preliminary data from its Phase I study that showed its oral Covid-19 tablet vaccine candidate, VXA-CoV2-1, triggered multiple immune responses against SARS-CoV-2 antigens.

It proved generally well-tolerated and immunogenic as measured by multiple markers of an immune response to the antigens.

The study is assessing the safety and immunogenicity of VXA-CoV2-1 vaccine with multiple dosing schedules.

In the study, subjects were divided into three cohorts. The first cohort had five participants given two low doses of vaccine 29 days apart.

The remaining cohorts had 15 participants each, who received either single low or high dose of the vaccine.

According to preliminary results from a pooled analysis of all cohorts, VXA-CoV2-1 also triggered immune responses against antigens including CD8+ cytotoxic T-cell response to the viral Spike (S) protein.

Researchers also observed a high percentage in plasmablast cell number, an upregulation of the mucosal homing receptor, as well as an increase in proinflammatory Th1 cytokines.

In addition, data showed that IgA responses in serum and / or nasal swab samples were observed in all of two dose subjects.